These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 30550765)

  • 1. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
    Shrestha P; Adepu S; Vivès RR; Masri RE; Klooster A; Kaptein F; Dam W; Bakker SJL; van Goor H; van de Sluis B; van den Born J
    J Am Soc Nephrol; 2021 Jun; 32(6):1371-1388. PubMed ID: 33758009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
    Zheng-Lin B; Ortiz A
    Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 in kidney disease.
    Schmit D; Fliser D; Speer T
    Nephrol Dial Transplant; 2019 Aug; 34(8):1266-1271. PubMed ID: 31190079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Katsiki N; Mikhailidis DP; Banach M
    Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.